Early treatment of rheumatoid arthritis (RA) with disease-modifying antirheumatic drugs will improve the outcome significantly. Early diagnosis of RA continues to be a challenge. The disease needs to be distinguished from other self-limiting arthritis and connective tissue disease. Currently available autoantibodies like rheumatoid factors and anticitrullinated cyclic peptide have limited sensitivity and specificity. RA, being a heterogeneous disease, with no unique or distinct defect that has been described, is less likely to have a single pathognomonic marker. There are defined predisposing genetic factors, cell characteristics, cytokine changes, autoantibodies, and products of disease process that have been demonstrated to distinguish rheumatoid from normal and other arthritis. Studies have demonstrated that combinations of factors allow for more specific RA diagnosis; however, when considerations are given to the factors separately, sensitivity increases at the cost of specificity. The present review briefly describes the value of some of the candidate factors and their combinations as diagnostic markers of early RA. Well-designed multicenter studies to evaluate these combinations using a scoring system are recommended for the development of precise and widely applicable biomarkers for early diagnosis of RA.
Introduction
Rheumatoid arthritis (RA) affects 1% of the population across the globe. The disease, being a chronic erosive synovitis with slow progression into systemic disease, results in significant impairment in quality of life and reduces life expectancy. The current evidence in the treatment of RA has demonstrated that early and effective intervention will reduce the incidence of deformities, and, in a few instances, a long lasting remission. 1 RA has to be differentiated, during early clinical presentation, from self-limiting viral arthritis, reactive arthritis, and even persisting nonerosive synovitis of systemic lupus erythematosus. Often, the self-limiting true RA needs to be identified, since it may not need long-term disease modifying antirheumatic drugs. Early arthritis clinics across the world have observed the following facts: 1) more than 50% of the patients who have synovitis at presentation resolve spontaneously over a period of time; 2,3 and 2) the remaining patients with chronic progressive arthritis may develop a well-defined syndrome, such as RA or connective tissue disease, or continue to experience undifferentiated arthritis. 2, 4, 5 The current challenge is to differentiate these two types of patients, in order to treat them appropriately. Inflammation is present in all the forms of arthritis and, hence, the markers of inflammation become nonspecific to differentiate inflammatory arthritis. However, the characteristic features which differentiate these two types, in earlier presentation of arthritis, will greatly assist in improving the care of RA with early interventions. This factor makes early diagnostic biomarkers one of the actively researched areas in management of RA.
A diagnostic biomarker, by definition, should be an objective, quantifiable characteristic of biological processes which helps in accurate diagnosis of the condition. It should consist of the following three characteristics: 1) analytical validation; 2) qualification; and 3) utilization. The current review attempts to analyze the available biomarkers for diagnosis of early RA.
Biomarkers in early RA: complexities
It is worthwhile to explore the complexity of the disease, before taking up an analysis of the biomarkers for early diagnosis of RA. RA is a heterogeneous disease in its clinical presentation as well as in its serological markers. The disease may vary from a very mild, self-limiting disease to an aggressive one with many different systemic involvements. Persisting inflammation, predominantly in the joints, is the hallmark of RA. However, simultaneous inflammation in areas other than joints cannot be excluded during the pathological process of RA. The defects in RA occur at three levels culminating in persisting inflammation. 6 The defect in RA can be at three different levels: level 1 -the site of inflammation, such as synovium, where the autoreactive and inflammatory cells proliferate; level 2 -the interface of regulatory processes, such as peripheral tolerance mechanism; and level 3 -the central level of regulation of autoimmunity. These levels are arbitrary and often overlap; all possible defects of these levels are described in RA. Another major challenge is that the changes triggering the disease and the subsequent process of development may differ between patient groups. Presumably, the changes at the regulatory levels leading to persistent inflammation, and those inhibiting reversible processes, may be unique to RA. However, changes in RA described in published literature, and the published biological modeling based on them, appear to be cumulative, and the clinical characteristics of presentation of RA may be proportionate to the pathological process (defects). There is no unique defect described in RA to date, which could account for the development and perpetuation of the disease; additionally, RA develops over a period of time. As a simple example, studies on rheumatoid factor (RF) as well as antibody to the cyclic citrullinated peptide (CCP) (anti-CCP) have demonstrated appearance of RF and anti-CCP in circulation well before disease development in a significant percentage of patients. 7 It is also observed that many patients with the antibody may not develop the disease, and a significant proportion of diagnosed RA patients do not develop these antibodies to a detectable limit. Hence, it is unlikely that a single specific marker represents the complex stepwise errors occurring in the development of RA. The probable steps leading to the development and propagation of RA are represented in Figure 1 . Current understanding of the therapy and a need for early intervention for better outcome of RA dictate the search for an ideal biomarker that can accurately predict and help to subclassify the disease activity, in order to plan an effective intervention.
Factors constituting the various steps, along with the probable constituents of the steps involved, as described in the literature, and the proposed mechanism of development of disease are shown in Figure 2 . A few of the parameters described in published literature are depicted in the figure at their probable location in the disease process. A major limitation of this representation is that the flow and sequence of pathological process is not as simple and straightforward as represented in the figure. As appraised by various 
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Biomarkers in early rheumatoid arthritis publications, autoantibodies may be present in very early courses of the disease. 7 In autoimmune diseases including RA, inflammation is the ultimate pathological process which causes damages and explains the majority of clinical manifestations. Hence, measuring inflammation and the markers representing inflammation can serve as a marker of disease activity, rather than representing the unique nature of the disease. Thus, a diagnostic biomarker of inflammation will not serve as a specific marker, as RA is a multifaceted disease represented by its clinical characteristics and pathological processes. Table 1 represents the factors that form the basis of this heterogeneity. The processes include dysregulation of proinflammatory factors, anti-inflammatory factors, or both. The heterogeneity of the disease has been attributed to differences in the activation of immune competent cells, cytokines, and expression of different receptors, partially or completely influenced by genetic status. [8] [9] [10] [11] [12] In view of these perspectives, identifying a single biomarker to diagnose RA is theoretically not possible.
Studies exploring single biomarkers such as an autoantibody have limited sensitivity, but a few of them have a good specificity. In contrast, studies of genetic polymorphism and clinical severity have demonstrated that a combination of biomarkers have more predictive strength than single biomarkers. IL-6 and IL-10 genotype polymorphism along with presence of RF and anti-CCP, 13 TNF polymorphism with development of disease in familial clusters, and HLA DRB1 shared epitope and anti-CCP 14 in development of disease are good examples of such combination of biomarkers. Consequently, a single biomarker may not sufficiently predict or identify all of the early RA patients. We present here a review of various preliminary studies dealing with the specificity and sensitivity of several possible markers, and the current status of these biomarkers. 
Biomarkers in early RA: current scenario
As evident from Figure 2 , cell numbers, characteristics and functions, different autoantibodies, cytokine levels, disease features by imaging, and products of disease process that appear at different stages of the progression of RA have been described and their utility as diagnostic markers of RA has been explored. The rest of the article provides a summary of the current state of each class of potential markers. Tables 2-5 present the specificity and sensitivity of some of the biomarkers from current published data, and the biomarkers are grouped according to their position in the scheme (Figure 2 ).
environmental and genetic markers for the risk of RA
The presence of a risk factor in patients presenting with arthritis can serve as a predictive marker or as a factor to help in confirming the diagnosis. The studies which have looked into the gene expression signature in CD4 cells could reasonably classify the patients who develop RA subsequently. 15 However, the test performed better in the anti-citrullinated peptide antibody (ACPA)-negative subset than the positive subset. The changes in CD4 cells have been described to be specific to the ACPA-negative group. In analysis of the susceptible epitope (SE) genes, which were defined as DR B1*0404 and DR B1*0401 when analyzed in both the patients and controls, the respective sensitivity and specificity figures for carriers of two SE genes were 28% (16/57) and 95%, respectively. The specificity for the B1*0401 allele (74%) was higher than that for SE given either B1*0401 or B1*0404, but the sensitivity increased to 60%. The frequencies of the presence of one or both of the SE genes studied in pre-RA patients were significantly greater than in the controls. 16 The PTPN22 1858C/T polymorphism was originally associated with type 1 diabetes, and later with other autoimmune diseases and RA. The PTPN-22 CT + TT was positive in 39.3% of 35 pre-patients of RA when prescreened, compared to only 19.7% of 71 normal controls. This estimated a sensitivity of 
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Biomarkers in early rheumatoid arthritis 39.3% and specificity of 80.3%, suggesting that presence of a susceptibility marker increases the positive predictive value or odds ratio in favor of the disease. 17 The meta-analysis suggests HLA DR B1*0401 has an odds ratio of 4.41 whereas that for PTPN22 is 1.94. 18 Increased relative risk of susceptibility improves sensitivity of detection, whereas the strength in causation will improve the specificity. However, given that the prevalence of genes in the community is on the higher side, they are not specific to diagnosis but do improve the positive predictive value of a pathological marker. The association of RA with its susceptibility markers is not very strong. The majority of susceptibility markers have very limited predictability when screened in an asymptomatic population.
Regulatory factors as markers of RA
RA is an immunological disease. There are characteristic changes expected to earmark the disease process and these changes will be observed to be statistically different from normal. Elevated activated CD8 cells, CD19 B-cells are seen to be present in RA compared to healthy controls. 19 Reduced levels of regulatory CD4+ CD25 high T-cells and T helper 17 CD4+ T-cells have been observed in the case of RA. 20, 21 Similarly, altered T-cell proliferation kinetics, serum 
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Biomarkers in early rheumatoid arthritis levels of IL-7, and type 1 interferon (IFN) score are seen in RA. [22] [23] [24] Though the differences are seen in early RA patients, there are few studies which have evaluated the specificity and sensitivity of these differences with reference to other rheumatic disease and normal controls. The studies evaluating T-cell kinetics and IFN signature have shown higher sensitivity and specificity (Table 3) , but there are limited experiences with these tests. 
Markers of early RA (reference) Specificity (%) Sensitivity (%) Positivity (%) Observation/detection
Anti-(Gly-CII) ( 
Autoantibody markers
Currently, autoantibodies to RF and CCP are well established markers of RA. Numerous studies have evaluated the utility of anti-RF, 16, 17, 22, [25] [26] [27] anti-CCP, 16, 17, 22, [26] [27] [28] [29] [30] [31] [32] and their variants. Antibodies to modified type II collagens, 33 degradation products of type II collagen, 34 vimetin, 27, 31 stress-related proteins, 35 and other peptides 30, 36 have also been explored recently. The specificity and sensitivity of a few autoantibodies are presented in Table 4 . A single autoantibody has a sensitivity ranging from 30%-70% and a few of them have a better specificity. Use of a single antibody as a marker increases sensitivity, while a combination of them increases specificity. In spite of this, 10%-30% of RA patients in early stages of the disease may not have any defined autoantibody, making it difficult to predict impending RA based on autoantibodies.
Degradation products and secreted products
The degradation products and secreted products, like C-X-C motif chemokine 13 (CXCL13), at sites of inflammation can serve as a marker of pathology. 37 Similarly, elevated ficolin 3, which is a humoral molecule of the innate immune system that recognizes carbohydrate molecules on pathogens, are differentially elevated in patients of RA. 38 Similarly, transthyretin, a thyroxine binding protein, is elevated in early RA. 39 Another metabolic product, asymmetric dimethyl-arginine, has been shown to be elevated in comparison to healthy con-trols, but is not a specific marker of arthritis. Reduced serum apelin has also been observed in a few patients. 40
Combinations of biomarkers
The heterogeneity of the disease, explained above, precludes the argument that a single biomarker could be specific as well as sensitive. Development of combined predictors or biomarkers should fulfill the obligation of being specific as well as sensitive. We analyze here the possibility of utilization of combined biomarkers and the available literature to support the concept ( Table 6 ).
Combination of autoantibodies
The American College of Rheumatology (ACR) criteria, which incorporate both clinical and laboratory parameters in diagnosis of RA, are more sensitive and specific than individual features put together. The recently developed ACR criteria have been estimated to possess an overall sensitivity of 82% and specificity of 61% when applied to the intended target population. 41, 42 The rate of identification of RA increases when RF and anti-CCP are used separately with the clinical features. This is one of the reasons for the increased sensitivity of newer ACR/European League Against Rheumatism (EULAR) criteria. Studies have reported 5%-13% of patients to be positive for anti-CCP in RF-negative RA population. Thus, if anti-CCP is used separately, there is a possibility of diagnosing an additional 10% of RA-suspected patients. 43 In isolation, RF and anti-CCP have lower specificity. A recent meta-analysis suggested a pooled sensitivity and specificity of 67% (confidence interval [CI] 65-68) and 95% (CI 95-96), respectively, for anti-CCP antibody, and 69% (CI 68-70) and 85% (CI 84-86) for immunoglobulin (Ig)M-RF. 44 However, when both RF and anti-CCP are combined, specificity increases to 99%-100%. 43 In a novel study using combined multiplex cytofluorimetric assay, combination of anti-CCP with RF appeared to be more sensitive (100%) and specific (87%) than the nephelometric assay for RF detection. 45 The greatest challenge is when patients do not have all the clinical characteristics typical of RA. The specificity and sensitivity of anti-CCP in such a case were 96.1% and 63.4%, respectively. 46 The antibodies like anti-CCP, RF-IgA, RF-IgM, and RF-IgG appear in a significant proportion of RA patients, much before the development of clinical disease. 7 Even the specificity for the prediction of the onset of RA in a pre-arthritis sample increased when two antibodies -anti-CCP and an RF isotype -were combined while the sensitivity was reduced. Thus, the combination of biomarkers may enhance the specificity at the cost of sensitivity, but this can be compensated by using matrices where an adequately weighted scoring system is used both individually and in combination. The choice of combination and use of multiple autoantibodies are expected to enhance both sensitivity and specificity. Antibodies against carbamylated fetal calf serum (anti-Ca-FCS) and carbamylated-fibrinogen (anti-Ca-Fib) were present to the extent of 27% and 38%, respectively, in serum samples of blood donors prior to the diagnosis of RA. Both anti-Ca-FCS and anti-Ca-Fib could be detected many years before the onset of RA. 47 Anti-carbamylated protein antibodies as well as ACPA are, on average, detected earlier than IgM-RF. 48 
Combination of biomarkers from different pathological processes
Genetic susceptibility and Auto-antibody positivity Anti-CCP and genetic markers individually do not have high specificity and relative risk prediction. Berglin et al have attempted to analyze the predictability of development of RA using a combination of an autoantibody (anti-CCP) and a shared epitope allele: HLA DRB1*0401 or B1*0404 (SE HLA DR). 16 They have demonstrated increased predictability as well as improved specificity in the prediction of RA. In the same way, a combination of a single nucleotide polymorphism in the PTPN22 gene encoding the lymphoid protein tyrosine phosphatase and the presence of a detectable level of anti-CCP have shown improved predictability for the development of RA and also the increased specificity of prediction. 17 The prediction is superior to SE HLA DR alone or in combination. The presence of PTPN22 1858T variant (CT + TT) and anti-CCP had a specificity of 100% with almost 20-times increased strength of predictability. These studies highlight the fact that the presence of susceptibility markers improves the positive predictive value of an add-on test.
Addition of activation markers
Chemotactic activation marker monocyte chemotactic protein-1 (MCP1) was increased with the onset of clinical disease and elevation of high-sensitivity C-reactive protein (hsCRP) and IL-6. 49 In a study identifying the predictors of RA in undifferentiated arthritis, markers like serum IL-7 and ACPA, and their combination with disease activity score (DAS) of 44, increased the specificity of prediction. 23 The changes, like reduced T helper 17 cells, IFN signature, and reduced regulatory CD4+ CD25 high T-cells in autoantibody positive patients, exhibit an increased specificity. 20, 21, 24 
Clinical features and lab parameters
Leiden score, which includes both clinical and lab parameters, helps in predicting the probability of undifferentiated arthritis progressing to RA. The score consists of seven variables: symptom duration at first visit; morning stiffness for .1 hour; arthritis in more than three joints; bilateral compression pain in the metatarsophalangeal joints; RF positivity; anti-CCP positivity; and the presence of erosion in hands/ feet. 50 The newer ACR/EULAR criteria could diagnose RA earlier than previous ACR criteria, but still lacks the desired sensitivity and specificity. In a meta-analysis of these criteria, pooled sensitivity and specificity for RA (defined by different reference standards) were 0.82 (95% CI 0.79-0.84) and 0.61 (95% CI 0.59-0.64), respectively. 42 The increased sensitivity of newer criteria is at the cost of specificity, evident on comparison with the previous criteria. In a follow-up study of patients categorized as having undifferentiated inflammatory arthritis, 24% developed RA. Anti-CCP and Leiden score were able to categorize only 6% and 1% into the group that predicted development of RA, respectively. 51 Observations such as this one point to the fact that inclusion of nonspecific and nondiscriminatory markers, either biological markers or clinical features, can improve sensitivity but with a reduction in specificity.
Differential specification should be picked from the pathways RA is a heterogeneous and dynamic disease. A single or a pooled biomarker may not be beneficial for the entire RA Current Biomarker Findings downloaded from https://www.dovepress.com/ by 54.70.40.11 on 17-Oct-2019 For personal use only. population, especially in the early course of the disease. The question of utmost importance is to identify the best markers and to choose them for further studies. Hence, it is preferable to select factors or molecules that are specific to RA pathogenesis and present in a significant proportion of RA population. For instance, utilization of a cartilage degradation marker as an additional marker for diagnosis and differentiation of RA did not remarkably contribute to diagnosis, since they are elevated in any form of inflammatory synovitis. The high diagnostic specificity of anti-CCP antibodies for RA was observed in a prospective population-based study of very early arthritis. Raised serum cartilage oligomeric matrix protein levels were common in all diagnosis groups in this series, indicating cartilage degradation is not unique to RA. The specificity was better and significant for anti-CCP, relative to cartilage oligomeric matrix protein. 52 The inflammatory markers, like hsCRP, represent activation of inflammation and suffer from nonspecificity; hence, they will not be suitable as diagnostic markers. This fact is evidenced in a Finnish study where 19,072 C-reactive protein levels were demonstrated to be of no predictive value in patients expected to develop RA. 53
Conclusion
A dynamic disease like RA is unlikely to have a single, unique biomarker to diagnose or predict the development of disease. A selected factor or molecule should be specific to RA, sensitive to the progression of disease, and cover a wide range of RA patients in order to qualify as a suitable biomarker. Only a combination of factors appears to fulfill all of these requirements. Some of the promising biomarker combinations include: change in immunological parameters like cell kinetics with the appearance of autoantibodies; specific cytokine changes; and other markers of disease susceptibility.
Multicenter studies exploring these factors should help improve their quality as biomarkers of early RA.
